Latest News - Allegro Ophthalmics

Wednesday, August 09, 2017 | Clinical Trials, Retina, Allegro Ophthalmics

Allegro Ophthalmics Announces Positive Topline Results From DEL MAR Phase 2B Stage 2 Trial Evaluating Luminate in Patients With DME

Allegro Ophthalmics announced that the DEL MAR Phase 2b Stage 2 clinical trial met its primary endpoint when used as a sequential therapy in patients with diabetic macular edema (DME). The study evalu…

Read the full story

Monday, July 24, 2017 | Earnings & Financials, Allegro Ophthalmics

Allegro Ophthalmics Secures $10.7 Million in Private Financing

Allegro Ophthalmics announced the completion of a private round of equity financing for $10.7 million. With this infusion of capital, the company is positioned to reach future corporate milestones. Th…

Read the full story

Tuesday, March 07, 2017 | Management/Leadership, Allegro Ophthalmics

Allegro Ophthalmics Names Melvin Sarayba, MD, Vice President Of Clinical Affairs

Allegro Ophthalmics announced that Melvin Sarayba, MD, has joined the company as vice president of clinical affairs. In his new role, Dr. Sarayba is responsible for Allegro’s US and internationa…

Read the full story

Thursday, December 15, 2016 | Clinical Trials, Allegro Ophthalmics

Allegro Ophthalmics Completes Enrollment in DEL MAR Phase 2b Clinical Trial of Luminate for the Treatment of DME

Allegro Ophthalmics announced completion of enrollment in the second stage of its DEL MAR trial that is evaluating the safety and efficacy of Luminate in combination and as an adjunctive therapy…

Read the full story

Monday, November 21, 2016 | Management/Leadership, Allegro Ophthalmics

William J. Link, PhD, Joins Allegro Ophthalmics’ Board of Directors

Allegro Ophthalmics announced that William J. Link, PhD, has been elected to Allegro’s board of directors. Dr. Link is cofounder and a managing director of Versant Ventures, a global healthcare …

Read the full story

Thursday, October 13, 2016 | Clinical Trials, Retina, Allegro Ophthalmics

Allegro Ophthalmics Announces Positive Topline Results From DEL MAR Phase 2B Trial Evaluating Luminate in Patients with Diabetic Macular Edema

Allegro Ophthalmics announced that the DEL MAR phase 2b clinical trial evaluating Luminate (ALG-1001) in 136 patients with diabetic macular edema (DME) met its primary and secondary endpoints, demonst…

Read the full story

Monday, October 03, 2016 | Clinical Trials, Retina, Allegro Ophthalmics

Allegro Ophthalmics Announces Last Patient Enrolled in PACIFIC Phase 2b Clinical Trial of Luminate for Non-Proliferative Diabetic Retinopathy

Allegro Ophthalmics announced completion of enrollment in its PACIFIC phase 2b clinical trial that is evaluating the safety and efficacy of Luminate (ALG-1001) in inducing posterior vitreous detachmen…

Read the full story

Monday, August 01, 2016 | Management/Leadership, Allegro Ophthalmics

Ron Kurtz, MD, and Mark Livingston Join Allegro Ophthalmics’ Board of Directors

Allegro Ophthalmics announced that Ron Kurtz, MD, president and CEO of Calhoun Vision, and Mark Livingston, president and CEO of PrimaPharma, have been elected to Allegro’s board of directors. …

Read the full story

Tuesday, March 15, 2016 | Management/Leadership, Allegro Ophthalmics

Vicken Karageozian, MD, Named President and Chief Medical Officer of Allegro Ophthalmics

Allegro Ophthalmics announced two promotions within the company’s senior management team. Vicken Karageozian, MD, formerly Chief Technical Officer, has been promoted to President and Chief Medic…

Read the full story

Tuesday, January 05, 2016 | Clinical Trials, Allegro Ophthalmics

Allegro Ophthalmics Announces Last Patient Enrolled in DEL MAR Phase 2b Clinical Trial of Luminate for the Treatment of DME

Allegro Ophthalmics announced completion of enrollment in its DEL MAR Phase 2b trial that is evaluating the safety and efficacy of Luminate (ALG-1001) in patients with diabetic macular edema (DME). Th…

Read the full story

Wednesday, October 21, 2015 | Management/Leadership, Allegro Ophthalmics

Allegro Ophthalmics Names New Members to its Executive Management Team

Allegro Ophthalmics announced that Scott Cooper has joined the company as chief financial officer and vice president of business development, and that Mohamed Genead, MD, has been named executive medi…

Read the full story

Monday, July 13, 2015 | Clinical Trials, Allegro Ophthalmics

Allegro Ophthalmics Announces Positive Topline Results from Phase 2 Trial Evaluating Luminate in Patients With VMT or VMA

Allegro Ophthalmics announced that the phase 2 clinical trial of Luminate (ALG-1001) in patients with vitreomacular traction (VMT) or vitreomacular adhesion (VMA) met its primary endpoint, according t…

Read the full story

Monday, May 18, 2015 | Clinical Trials, Allegro Ophthalmics

Allegro Ophthalmics Announces Issuance of US Patent for First-in-Class Integrin Peptide Therapy Candidate Luminate

Allegro Ophthalmics announced that the United States Patent and Trademark Office has issued a patent (no. 9,018,352) covering the composition of matter of Allegro’s product candidate, Luminate (…

Read the full story

Monday, May 04, 2015 | Clinical Trials, Allegro Ophthalmics

Allegro Ophthalmics Begins Phase 2 Clinical Study of Luminate for Non-Proliferative Diabetic Retinopathy

Allegro Ophthalmics announced that it has begun enrolling patients in a phase 2 clinical trial that will evaluate the safety and efficacy of Allegro’s first-in-class integrin peptide therapy can…

Read the full story